

## ACO Name and Location

Accountable Care Coalition of Texas, Inc.  
4888 Loop Central Drive  
Suite 700  
Houston, Texas 77081

## ACO Primary Contact

Primary Contact Name	Erin Page
Primary Contact Phone Number	855-236-9820
Primary Contact Email Address	EPage@UniversalAmerican.com

## Organizational Information

### ACO participants:

ACO Participants	ACO Participant in Joint Venture (Enter Y or N)
N W HOUSTON FAMILY PRACTICE PA	N
Emmanuel N. Oriahi, MD	N
MEMORIAL PULMONOLGY PA	N
ONCOLOGY AND HEMATOLOGY CONSULTANTS OF HOUSTON PA	N
NEPHROLOGY AND HYPERTENSION SPECIALISTS PA	N
Ahmed Cardiology MD PA	N
Quest Diagnostics Clinical Laboratories Inc	N
THE DOAN OF VO CLINIC PA	N
Ana Torres	N
Mitzi T. Jimenez, MD, PA	N
Mitzi Jimenez	N
BICH NGUYEN MD PA	N
LEILA G. VIZIROV, M.D., P.A.	N
ACHIEVEMENT MEDICAL ASSOCIATES PA	N
CHARLES G HOLMSTEN MD AND ASSOCIATES	N
Sei Chang Oh, MD	N
Hugo M. Toro, MD., PA	N
HarlingenCriticalCarePA	N

The Dewitt Clinic, P.A.	N
FAROUK BARBANDI MD PA	N
Chi Si Choi, MD., PA	N
Peter Farha, MD	N
HOUSTON CHEST INTERNISTS	N
James A. Wilkerson, Jr., MD	N
Barbara E. Bush, M.D.	N
PULMONARY AND INTERNAL MEDICINE ASSOCIATES, L.L.P.	N
Medical Chest Associates, P.A.	N
HOUSTON NEPHROLOGY GROUP PA	N
DEVENDER D REDDY,M.D. P.A.	N
ONE MEDIC LANE PHYSICIANS PLLC	N
RAJINDER K BHALLA MD PA	N
Benjamin Interiano, MD., PA	N
Leroy Sterling	N
WILLIAMS FAMILY PRACTICE, P A	N
Ganesh P. Gupta MD., PA	N
Mobeen Mazhar, MD., PA	N

**ACO governing body:**

Member			Member's Voting Power	Membership Type	ACO Participant TIN Legal Business Name/DBA, if Applicable
Last Name	First Name	Title/Position			
Dewitt, MD	Robert	Chair	25%	ACO participant representative	The Dewitt Clinic, P.A.
Rabie, MD	Trevor	Voting Member	12.5%	ACO participant representative	Medical Chest Associates, PA
Wilkerson, MD	James	Voting Member	12.5%	ACO participant representative	James A. Wilkerson, Jr., MD
Toro, MD	Hugo	Voting	12.5%	ACO	Hugo M. Toro, MD.,

		Member		participant representative	PA
Vizirov, MD	Leila	Voting Member	12.5%	ACO participant representative	Leila G. Vizirov, M.D., P.A
Holmsten, MD	Walter	Voting Member	12.5%	ACO participant representative	CHARLES G HOLMSTEN MD AND ASSOCIATES
Holmsten, MD	Charles	Voting Member	12.5%	Medicare Beneficiary Representative	CHARLES G HOLMSTEN MD AND ASSOCIATES

**Key ACO clinical and administrative leadership:**

Erin Page	ACO Executive
Robert DeWitt	Medical Director
Michael Yount	Compliance Officer
Robert DeWitt, M.D.	Quality Assurance/Improvement Officer

**Associated committees and committee leadership:**

Committee Name	Committee Leader Name and Position
Quality Improvement & Care Coordination	Robert Dewitt, M.D. Chair

**Types of ACO participants, or combinations of participants, that formed the ACO:**

- Networks of individual practices of ACO professionals

**Shared Savings and Losses**

**Amount of Shared Savings/Losses**

- Second Agreement Period
  - Performance Year 2016, \$1,568,097
- First Agreement Period
  - Performance Year 2015, \$4,533,923
  - Performance Year 2014, \$6,335,569
  - Performance Year 2013, \$9,357,388

**Shared Savings Distribution**

- Second Agreement Period
  - Performance Year 2016

- Proportion invested in infrastructure: 25%
- Proportion invested in redesigned care processes/resources: 49%
- Proportion of distribution to ACO participants: 25%
- First Agreement Period
  - Performance Year 2015
    - Proportion invested in infrastructure: 26%
    - Proportion invested in redesigned care processes/resources: 48%
    - Proportion of distribution to ACO participants: 26%
  - Performance Year 2014
    - Proportion invested in infrastructure: 35%
    - Proportion invested in redesigned care processes/resources: 30%
    - Proportion of distribution to ACO participants: 35%
  - Performance Year 2013
    - Proportion invested in infrastructure: 11%
    - Proportion invested in redesigned care processes/resources: 48%
    - Proportion of distribution to ACO participants: 26%

## Quality Performance Results

2016 Quality Performance Results:

ACO#	Measure Name	Rate	ACO Mean
ACO-1	CAHPS: Getting Timely Care, Appointments, and Information	80.18	79.9
ACO-2	CAHPS: How Well Your Providers Communicate	93.67	92.63
ACO-3	CAHPS: Patients' Rating of Provider	92.71	91.93
ACO-4	CAHPS: Access to Specialists	83.33	83.52
ACO-5	CAHPS: Health Promotion and Education	59.06	60
ACO-6	CAHPS: Shared Decision Making	73.51	75.28
ACO-7	CAHPS: Health Status/Functional Status	73.02	71.82
ACO-34	CAHPS: Stewardship of Patient Resources	32.9	27.52
ACO-8	Risk-Standardized, All Condition Readmission	14.81	14.7

ACO-35	Skilled Nursing Facility 30-Day All-Cause Readmission Measure (SNFRM)	17.98	18.17
ACO-36	All-Cause Unplanned Admissions for Patients with Diabetes	50.34	53.2
ACO-37	All-Cause Unplanned Admissions for Patients with Heart Failure	82.23	75.23
ACO-38	All-Cause Unplanned Admissions for Patients with Multiple Chronic Conditions	56.72	59.81
ACO-9	Ambulatory Sensitive Conditions Admissions: Chronic Obstructive Pulmonary Disease or Asthma in Older Adults (AHRQ Prevention Quality Indicator (PQI) #5)	10.37	9.27
ACO-10	Ambulatory Sensitive Conditions Admissions: Heart Failure (AHRQ Prevention Quality Indicator (PQI) #8 )	12.59	14.53
ACO-11	Percent of PCPs who Successfully Meet Meaningful Use Requirements	52.78	82.72
ACO-39	Documentation of Current Medications in the Medical Record	85.27	87.54
ACO-13	Falls: Screening for Future Fall Risk	49.92	64.04
ACO-14	Preventive Care and Screening: Influenza Immunization	70.64	68.32
ACO-15	Pneumonia Vaccination Status for Older Adults	62.05	69.21
ACO-16	Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow Up	71.19	74.45
ACO-17	Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention	85.67	90.98
ACO-18	Preventive Care and Screening: Screening for Clinical Depression and Follow-up Plan	49.82	53.63
ACO-19	Colorectal Cancer Screening	56.46	61.52
ACO-20	Breast Cancer Screening	50.83	67.61
ACO-21	Preventive Care and Screening: Screening for High Blood Pressure and Follow-up Documented	90.03	76.84
ACO-42	Statin Therapy for the Prevention and Treatment of Cardiovascular Disease	71	77.72
ACO-27	Diabetes Mellitus: Hemoglobin A1c Poor Control	23.69	18.24
ACO-41	Diabetes: Eye Exam	38.68	44.94
ACO-28	Hypertension (HTN): Controlling High Blood Pressure	70.95	70.52

ACO-30	Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic	74.61	85.05
ACO-31	Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)	90.91	88.67
ACO-33	Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy – for patients with CAD and Diabetes or Left Ventricular Systolic Dysfunction (LVEF<40%)	82.91	79.67

Please note, the ACO-40 Depression Remission at 12 months quality measure is not included in public reporting due to low samples.

- For 2016 Quality Performance Results please visit: <https://data.cms.gov/Special-Programs-Initiatives-Medicare-Shared-Savin/2016-Shared-Savings-Program-SSP-Accountable-Care-O/3jk5-q6dr/data>
- For 2015 Quality Performance Results please visit: <https://data.cms.gov/Special-Programs-Initiatives-Medicare-Shared-Savin/Medicare-Shared-Savings-Program-Accountable-Care-O/x8va-z7cu>
- For 2014 Quality Performance Results please visit: <https://data.cms.gov/Special-Programs-Initiatives-Medicare-Shared-Savin/Medicare-Shared-Savings-Program-Accountable-Care-O/ucce-hhpu>
- For 2013 Quality Performance Results please visit: <https://data.cms.gov/Special-Programs-Initiatives-Medicare-Shared-Savin/Medicare-Shared-Savings-Program-Accountable-Care-O/yuq5-65xt>

Note: In the Quality Performance Results file(s) above, search for “Accountable Care Coalition of Texas, Inc.” to view the quality performance results. This ACO can also be found by using the ACO ID A05273 in the public use files on data.cms.gov.

### Payment Rule Waivers

- No, our ACO does not use the SNF 3-Day Rule Waiver.

## Arrangements Disclosed

### REQUIRED PUBLIC DISCLOSURE FOR THE ACO PARTICIPATION WAIVER

The Accountable Care Coalition of Texas, Inc. (the “ACO”) participates in the Medicare Shared Savings Program (“MSSP”) under a contract with the Centers for Medicare & Medicaid Services (“CMS”). The Secretary of the Department of Health and Human Services has provided certain waivers of federal fraud and abuse laws in connection with the MSSP. On October 24, 2016, the Management Committee of the ACO met at a duly called meeting to discuss an arrangement with Curant Health Georgia, LLC and Curant Health Florida, LLC (collectively “Curant”) under which Curant will provide a grant of funds to assist the ACO’s efforts with respect to the MSSP. Consistent with 42 CFR 425.106(b)(3), after discussing the proposed arrangement with Curant, the Management Committee made a bona fide determination that an arrangement with Curant as described below is reasonably related to the purpose of the MSSP and authorized such

arrangement. The collaboration is related to the purposes of the MSSP as it augments the ACO's ability to:

- Promote evidence-based medicine and patient engagement;
- Meet the requirements for reporting quality and cost measures coordinating care;
- Establish clinical and administrative systems;
- Meet the clinical integration requirements of the Medicare Shared Savings Program;
- Evaluate the health needs of the ACO's aligned population;
- Communicate clinical knowledge and evidence based medicine to Medicare beneficiaries; and
- Develop standards for beneficiary access and communication, including beneficiary access to medical records.